Navigation Links
Impending FDA Approval Decision on the First HIV Integrase Inhibitor Can Have Significant Impact for Patients
Date:10/12/2007

ANALYST AVAILABLE TO COMMENT ON THE MARKET FORECAST FOR THE DRUG

WALTHAM, Mass., Oct. 12 /PRNewswire/ -- Dr. Sylvia Eash, Ph.D., analyst at Decision Resources, is available to discuss the impact of the Food and Drug Administration's (FDA) possible approval of Merck's Isentress, the first integrase inhibitor drug which blocks the ability of the HIV virus to replicate and infect new cells.

Integrase inhibitors are a novel class of HIV drugs aimed at a previously unexploited viral target. They are a key new class that will expand therapeutic options for HIV patients and stand out as one of the most promising emerging classes in development for HIV. The reported efficacy and safety data from clinical trials of Isentress indicate that the product is highly efficacious, safe, well tolerated in both treatment-naive and treatment-experienced HIV patients. The clinical data on Isentress presented to date suggests that there is significant opportunity for follow-on agents in this new class of HIV drugs.

Isentress is expected to launch during the fourth quarter of 2007, according to Merck.

Dr. Eash can provide:

-- Insight on the class of integrase inhibitors and particularly Isentress

and its potential effect on other drugs in the HIV market.

-- Key factors that will have an impact on Isentress's uptake and use. How

will Isentress be positioned in the lines of HIV treatment?

-- The main drivers and barriers for its use. What is the forecast for

Isentress? Which drugs will be its main competition?

-- Key thought leaders' perceptions about Isentress.

-- Isentress's impact on the HIV market and on the overall HIV therapeutic

approach.

Sylvia Eash, Ph.D., is an analyst with Decision Resources Infectious Disease group, where she evaluates emerging therapies and develops market forecasts. She has a doctoral degree in pathobiology from Brown University. Dr. Eash is the author of several peer-reviewed primary literature and review articles, and she is a member of the American Society for Microbiology and the International Society of Neurovirology.

To talk with Dr. Eash, please contact Erica Ames at 781-296-2583 or eames@dresources.com.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Erica Ames

781-296-2583

eames@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. A Vaccine for the impending pandemic Avian Influenza
2. India warned of Impending AIDS Disaster
3. 3-D Ultrasound Identifies Women at Risk for Impending Preterm Birth
4. Now, Cellphones That Alert Against Impending Lightning Strikes
5. WHO Gives Its Approval For Bird Flu Test Kit
6. Ranbaxy gets US FDA approval for Lisinopril
7. Approval for DNA test to detect cystic fibrosis
8. Aurobindo gets U.S. FDA approval for Cephalexin
9. Cadila gets US FDA approval for Promethazine tablets
10. Vaccine For Cervical Cancer Awaits Approval
11. Anti-obesity drugs for FDA approval
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... 20, 2017 , ... “Code Word: Chocolate Biscuit”: a biographical account following a man who went ... creation of published author, Marlyn Ivey, born in Lynn Haven, Florida and at the age ... at 19 years of age, he joined the Navy and got married right out of ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Knowledge is God’s Lighthouse”: ... by faith. “Knowledge is God’s Lighthouse” is the creation of published author, Gene Gaapf, ... and poetry collections. , “I have been writing since high school and have ...
(Date:1/19/2017)... ... , ... Next week after January 20th, the fear for many is that ... health needs of over 30 million. Many interviews with Dr. Carol Francis at the ... servants were suppose to prioritize. Interviews provided below. , Among those present ...
(Date:1/19/2017)... ... 2017 , ... WhoHaha , a digital media company dedicated to creating ... to produce a three-part video series that uses humor to highlight ways to improve ... of AHA’s Healthy For Good™ movement, which is designed to inspire all Americans to ...
(Date:1/19/2017)... Scotch Plains, NJ (PRWEB) , ... January 19, ... ... a board certified dermatologist by the American Board of Dermatology and fellowship trained ... Institute of the National Institutes of Health, Dr. Li completed his internship in ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... , Jan. 20, 2017  Ethicon ... acquired Megadyne Medical Products, Inc., a privately ... and markets electrosurgical tools used in operating ... intelligence of Ethicon,s* advanced energy devices with ... a major step forward in Ethicon,s goal ...
(Date:1/20/2017)... , Jan. 20, 2017  Palladian Health, a ... announced the launch of an opioid management program ... on opioids and helps stem the growing tide ... prescribed to treat chronic non-cancer pain (back pain, ... risks and lack of evidence regarding long-term effectiveness. ...
(Date:1/20/2017)... , January 20, 2017 Avillion LLP, ... appointment of Mark Weinberg , MD MBA as Chief Medical ... , USA . ... Dr Weinberg has spent more than 17 years ... 20" pharma companies to micro-cap biotech. Over the course of his ...
Breaking Medicine Technology: